Investors & Media

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Flex Pharma Partners with Five Time World Champion Triathlete Craig “Crowie” Alexander

KONA, Hawaii--(BUSINESS WIRE)--Oct. 7, 2015-- Click to Tweet this News

Flex Pharma, Inc. (NASDAQ: FLKS), a company developing innovative and proprietary treatments for exercise-associated muscle cramps, has signed an exclusive partnership with World Champion triathlete Craig “Crowie” Alexander from Australia around its scientific breakthrough to prevent and treat muscle cramps. Alexander is a three-time IRONMAN® World Champion and two-time IRONMAN 70.3 World Champion. He is currently the course record holder for the IRONMAN World Championship.

“I’m excited to partner with Flex Pharma because the company’s scientific breakthrough formula is born out of a love for sport and helping athletes push beyond what they thought possible,” said Alexander. “This discovery is a must-have tool for me on my hard training days and beyond. The benefits may help you surpass anything you thought you were capable of.”

As part of the partnership, Alexander will incorporate Flex Pharma’s proprietary discovery as part of training, racing, and coaching regimens under his Sansego brand.

“It’s an honor to be working with Craig. Our partnership highlights how this proprietary formula can help change and improve athletes’ performances dramatically by eliminating the often debilitating cramps that plague endurance athletes. Long known as the ‘King of Kona,’ Crowie has a definitive sense of what is essential for an athlete to achieve the ultimate in endurance racing,” said Marina Hahn, President, Consumer Goods.

Flex Pharma’s discovery occurred after founder Dr. Rod MacKinnon, a Nobel Prize winning neuroscientist and endurance athlete, and his friend and colleague, Dr. Bruce Bean, Harvard neurobiology professor, were seized by muscle cramps while kayaking. Together, the scientists sought to understand the cause of cramping and to separate traditional assumptions from scientific reality. In doing so, they discovered what was at the time counter-intuitive: When it comes to preventing muscle cramps, it’s not about the muscle, it’s the nerve. Applying this innovative science to helping athletes, the Company is exploring other potential benefits that may help define a new category in nutrition: Neuromuscular Performance.

In addition to Alexander, many athletes around the world who are training for the IRONMAN World Championship presented by GoPro and suffer from muscle cramps have already been incorporating Flex Pharma’s revolutionary discovery into their training and racing. Representatives from Flex Pharma will be available October 7-10 at the IRONMAN Village Expo booth for sampling. The Company expects to begin commercializing its consumer product in the first half of 2016.

To learn more about Flex Pharma’s scientific discovery, visit Individuals also can follow @itsthenerve on Twitter and Instagram, and become a fan on Facebook at

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Individuals can follow the Company on Twitter (@flexpharma) and the Company's website ( to see the latest progress of the Company's pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our plans to develop and commercialize our consumer products and the future availability and product features of our consumer products. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the status, timing, costs, results and interpretation of our studies; our ability to develop and commercialize our consumer products; anticipated positioning and product attributes of our consumer products; results of early studies as indicative of the results of future trials; and other factors discussed in greater detail under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Source: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications